{"id":52904,"date":"2026-01-05T22:27:04","date_gmt":"2026-01-05T14:27:04","guid":{"rendered":"https:\/\/flcube.com\/?p=52904"},"modified":"2026-01-05T22:27:06","modified_gmt":"2026-01-05T14:27:06","slug":"huadong-medicine-licenses-mc2s-pad-based-biomee-skincare-for-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52904","title":{"rendered":"Huadong Medicine Licenses MC2&#8217;s PAD\u2011Based Biomee Skincare for Greater China"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced an agreement with <strong>MC2 Therapeutics Ltd.<\/strong> (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain <strong>exclusive commercialization rights<\/strong> in <strong>Greater China<\/strong> (Mainland China, Hong Kong, Macau, Taiwan) for <strong>Biomee#1 and Biomee#2<\/strong> dermatological creams, expanding its <strong>PAD Technology\u2011based dermatology portfolio<\/strong> following the 2023 Wynzora acquisition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>MC2 Therapeutics Ltd. (subsidiary of MC2 Therapeutics A\/S)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Huadong Medicine Co., Ltd (000963.SZ)<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Biomee#1 and Biomee#2 creams<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (Mainland China, Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive commercialization<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>PAD (Patient\u2011Adaptive Delivery) Technology<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Daily skincare for dry skin and discomfort; Phase\u202fII POC trials for CKD\u2011associated pruritus (CKD\u2011aP) and vulvar lichen sclerosus (VLS)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-biomee-skincare-line\">Product Profile: Biomee Skincare Line<\/h2>\n\n\n\n<p><strong>Biomee#1 &amp; Biomee#2<\/strong> utilize <strong>MC2\u2019s PAD Technology<\/strong> to provide <strong>daily skin care and comfort<\/strong> for individuals prone to <strong>dry skin and irritation<\/strong>. Over\u2011the\u2011counter formulations offer <strong>excellent sensory comfort<\/strong> and <strong>effective soothing<\/strong> of skin irritation, based on overseas trials.<\/p>\n\n\n\n<p><strong>Clinical Development<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fII POC trials<\/strong> underway for <strong>CKD\u2011associated pruritus<\/strong> and <strong>vulvar lichen sclerosus (VLS)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: PAD Technology enhances <strong>skin barrier restoration<\/strong> and <strong>anti\u2011inflammatory delivery<\/strong><\/li>\n\n\n\n<li><strong>Clinical Differentiation<\/strong>: Addresses <strong>unmet need<\/strong> in <strong>chronic kidney disease patients<\/strong> suffering from intractable pruritus<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-pad-technology\">Technology Platform: PAD Technology<\/h2>\n\n\n\n<p><strong>Patient\u2011Adaptive Delivery (PAD) System<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Encapsulation technology<\/strong> that adapts to skin pH and moisture levels, providing <strong>sustained release<\/strong> of active ingredients<\/li>\n\n\n\n<li><strong>Proven Platform<\/strong>: Same technology utilized in <strong>Wynzora Cream<\/strong> (psoriasis therapy) licensed to Huadong Medicine in <strong>August\u202f2023<\/strong><\/li>\n\n\n\n<li><strong>Advantages<\/strong>: <strong>Enhanced penetration<\/strong>, <strong>reduced irritation<\/strong>, <strong>improved patient compliance<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Portfolio Synergy<\/strong>: Huadong Medicine now holds <strong>two PAD\u2011based dermatology assets<\/strong>, creating <strong>platform expertise<\/strong> for future in\u2011licensing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Dermatology &amp; Chronic Pruritus Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD\u2011aP Prevalence<\/strong>: <strong>30\u201140%<\/strong> of <strong>3.5\u202fmillion<\/strong> Chinese dialysis patients suffer from moderate\u2011to\u2011severe pruritus<\/li>\n\n\n\n<li><strong>VLS Prevalence<\/strong>: <strong>1\u20112%<\/strong> of adult women; <strong>500,000\u20111\u202fmillion<\/strong> patients in China<\/li>\n\n\n\n<li><strong>Dry Skin Market<\/strong>: <strong>\u00a545\u202fbillion<\/strong> (US$6.3\u202fB) OTC skincare market, growing at <strong>12% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Revenue Projections<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026\u20112027<\/strong>: <strong>\u00a5200\u2011300\u202fmillion<\/strong> (OTC Biomee sales)<\/li>\n\n\n\n<li><strong>2028\u20112029<\/strong>: <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (if CKD\u2011aP\/VLS indications approved)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a51.5\u202fbillion<\/strong> (US$210\u202fM) by 2030 across <strong>three indications<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Pricing<\/strong>: OTC Biomee expected at <strong>\u00a5150\u2011250<\/strong> per tube; prescription CKD\u2011aP\/VLS formulation at <strong>\u00a5800\u20111,200<\/strong> per month.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-strategic-rationale\">Financial Terms &amp; Strategic Rationale<\/h2>\n\n\n\n<p><strong>Deal Structure<\/strong>: Undisclosed upfront\/milestone terms typical for <strong>Phase\u202fII OTC\u2011to\u2011Rx pipeline assets<\/strong> (estimated <strong>USD\u202f15\u201125\u202fmillion<\/strong> upfront + milestones).<\/p>\n\n\n\n<p><strong>Strategic Logic<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Builds on <strong>2023 Wynzora deal<\/strong>, solidifying Huadong\u2019s <strong>dermatology leadership<\/strong><\/li>\n\n\n\n<li><strong>Platform Leverage<\/strong>: PAD Technology expertise reduces <strong>development risk<\/strong> for future assets<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Huadong\u2019s <strong>5,000\u2011person sales force<\/strong> covers <strong>3,000+ hospitals<\/strong> and <strong>40,000+ pharmacies<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Position<\/strong>: Huadong aims to become <strong>#2 dermatology player<\/strong> in China by 2028, behind <strong>J&amp;J<\/strong> but ahead of <strong>LEO Pharma<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Biomee\u2019s commercial launch timeline, clinical trial outcomes, market penetration, and revenue projections. Actual results may differ materially due to regulatory approvals, competitive responses, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52906,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[114,2287,887],"class_list":["post-52904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-huadong-medicine","tag-mc2-therapeutics","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Licenses MC2&#039;s PAD\u2011Based Biomee Skincare for Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Licenses MC2&#039;s PAD\u2011Based Biomee Skincare for Greater China\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T14:27:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T14:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Licenses MC2&#8217;s PAD\u2011Based Biomee Skincare for Greater China\",\"datePublished\":\"2026-01-05T14:27:04+00:00\",\"dateModified\":\"2026-01-05T14:27:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0504.webp\",\"keywords\":[\"Huadong Medicine\",\"MC2 Therapeutics\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52904#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52904\",\"name\":\"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0504.webp\",\"datePublished\":\"2026-01-05T14:27:04+00:00\",\"dateModified\":\"2026-01-05T14:27:06+00:00\",\"description\":\"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\\\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52904\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Licenses MC2&#8217;s PAD\u2011Based Biomee Skincare for Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52904","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China","og_description":"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.","og_url":"https:\/\/flcube.com\/?p=52904","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T14:27:04+00:00","article_modified_time":"2026-01-05T14:27:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Licenses MC2&#8217;s PAD\u2011Based Biomee Skincare for Greater China","datePublished":"2026-01-05T14:27:04+00:00","dateModified":"2026-01-05T14:27:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52904"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","keywords":["Huadong Medicine","MC2 Therapeutics","SHE: 000963"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52904#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52904","url":"https:\/\/flcube.com\/?p=52904","name":"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52904#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","datePublished":"2026-01-05T14:27:04+00:00","dateModified":"2026-01-05T14:27:06+00:00","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly\u2011owned subsidiary of MC2 Therapeutics A\/S) to obtain exclusive commercialization rights in Greater China (Mainland China, Hong Kong, Macau, Taiwan) for Biomee#1 and Biomee#2 dermatological creams, expanding its PAD Technology\u2011based dermatology portfolio following the 2023 Wynzora acquisition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52904"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52904#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","width":1080,"height":608,"caption":"Huadong Medicine Licenses MC2's PAD\u2011Based Biomee Skincare for Greater China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Licenses MC2&#8217;s PAD\u2011Based Biomee Skincare for Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52904"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52904\/revisions"}],"predecessor-version":[{"id":52907,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52904\/revisions\/52907"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52906"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}